Children's Hospital, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland.
Catheter Cardiovasc Interv. 2013 Jun 1;81(7):1174-9. doi: 10.1002/ccd.24621. Epub 2013 Feb 26.
To assess the strength of thrombin formation and determine the effects of unfractionated heparin (UFH) in children during cardiac catheterization.
UFH reduces the thrombotic risk related to catheterization but the effects of UFH on the coagulation system in children, and proper monitoring of UFH remain unclear.
We studied 42 patients aged 3-12 years undergoing catheterization. Twenty-seven received UFH (group A) and 15 patients did not (group B). Anticoagulation was assessed by measurements of plasma prothrombin fragment F1 + 2, thrombin-antithrombin (TAT) complexes, D-dimer, activated partial thromboplastin time (APTT), anti-FXa, and prothrombinase-induced clotting time (PiCT).
Markers of thrombin generation remained low during catheterization in group A. In group B, both F1 + 2 and TAT had increased significantly (P < 0.05) by the end of the procedure versus baseline and versus respective levels in group A. In group A, 15 min after heparinization, APTT was over 180 sec (in all patients), anti-FXa 1.4 U/ml (1.1-2.4 U/ml) and PiCT 1.5 U/ml (1.3-2.4 U/ml). Anti-FXa and PiCT were correlated (R = 0.84, P < 0.0001).
Thrombin generation was enhanced in patients who did not receive UFH, which may increase the risk of thrombotic complications. In group A, routine heparinization seemed excessive by all monitoring methods. UFH prevented an increase in prothrombin to thrombin conversion, resulting in unaltered fibrin formation. The current UFH protocol seemed to have no effect on postprocedural activation of coagulation. Further studies are needed to clarify adequate heparin dosing for children during cardiac catheterization to prevent thrombotic complications without predisposing the patient to bleeding complications.
评估凝血酶生成的强度,并确定普通肝素(UFH)在儿童心脏导管检查中的作用。
UFH 降低了与导管相关的血栓形成风险,但 UFH 对儿童凝血系统的影响以及 UFH 的适当监测仍不清楚。
我们研究了 42 名年龄在 3-12 岁之间接受导管检查的患者。27 名患者接受了 UFH(A 组),15 名患者未接受 UFH(B 组)。通过测量血浆凝血酶原片段 F1 + 2、凝血酶-抗凝血酶(TAT)复合物、D-二聚体、活化部分凝血活酶时间(APTT)、抗 FXa 和凝血酶原酶诱导的凝固时间(PiCT)来评估抗凝作用。
在 A 组中,在导管检查过程中,凝血酶生成标志物保持较低水平。在 B 组中,F1 + 2 和 TAT 在手术结束时与基线相比以及与 A 组的相应水平相比均显著增加(P < 0.05)。在 A 组中,肝素化 15 分钟后,APTT 超过 180 秒(所有患者),抗 FXa 为 1.4 U/ml(1.1-2.4 U/ml),PiCT 为 1.5 U/ml(1.3-2.4 U/ml)。抗 FXa 和 PiCT 呈正相关(R = 0.84,P < 0.0001)。
未接受 UFH 的患者凝血酶生成增强,这可能增加血栓并发症的风险。在 A 组中,所有监测方法均表明常规肝素化过量。UFH 阻止了凝血酶原向凝血酶的转化增加,从而使纤维蛋白形成保持不变。目前的 UFH 方案似乎对术后凝血的激活没有影响。需要进一步研究以确定儿童心脏导管检查期间适当的肝素剂量,以预防血栓并发症,而不会使患者容易发生出血并发症。